Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $29.00. They now have an "equal weight" rating on the stock.
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]
Viridian Therapeutics (NASDAQ:VRDN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.